Skip to main content

Decoding Tumor Plasticity: Integrative Analysis of Epigenetic Regulation and Microenvironmental Adaptation

74kviews
Editorial16 January 2026
Editorial: Decoding tumor plasticity: integrative analysis of epigenetic regulation and microenvironmental adaptation

pro-or anti-tumoral outcomes depending on environmental cues [3] . Harnessing this adaptability offers promising avenues for developing novel immunotherapeutic strategies. Dong and Zhao et al. highlighted the critical interaction between NK cells and head and neck squamous cell carcinoma (HNSCC), wherein NK cells exert direct cytotoxic and immunomodulatory effects. However, HNSCC evades NK cell surveillance through mechanisms such as downregulation of NKG2D ligands and the establishment of an immunosuppressive TME. Cetuximab, an anti-EGFR monoclonal antibody, enhances NK cell-mediated antibody-dependent cellular cytotoxicity and immunogenic modulation, improving outcomes in EGFR-overexpressing HNSCC. Emerging approachesincluding CAR-NK cells, cytokine-primed NK cells, and bispecific engagers-show clinical potential. However, challenges such as TGF-β-mediated suppression and metabolic competition within the TME must be addressed to optimize NK cell-based therapies. Combining EGFR inhibition with NK cell activation may offer a synergistic strategy for HNSCC treatment. In colorectal cancer (CRC), impaired NK cell infiltration and function within the TME have been observed, although the underlying mechanisms remain incompletely understood. Li and Wang et al. reported reduced SMAD4 expression in tumor-infiltrating NK cells, with SMAD4 overexpression enhancing NK cell cytotoxicity against CRC cells. Mechanistically, SMAD4 upregulates NKG2D expression via YTHDF2, a key downstream effector that regulates m6A-modified RNA metabolism. These findings establish the SMAD4-YTHDF2 axis as a critical regulator of NK cell anti-tumor activity and suggest SMAD4 as a potential therapeutic target for enhancing NK cell-based immunotherapy in CRC.Similarly, tumor-associated macrophages (TAMs) exhibit plasticity that allows them to facilitate immune evasion and promote tumor metastasis. TAMs can release cytokines that inhibit effector immune cells and attract additional immunosuppressive cells to the TME, highlighting their role as key regulators of tumor immune evasion [4] . Lung cancer (LC) remains a leading global malignancy, where tumor-associated macrophages (TAMs) is implicated in tumor progression and metastasis through their dynamic polarization into pro-tumor (M2-like) or anti-tumor (M1-like) phenotypes. The plasticity of TAMs, governed by complex signaling crosstalk within the TME, offers therapeutic opportunities to reprogram M2-like macrophages toward tumor-suppressive M1-like states. Li and Yuan et al's works highlight synthetic and natural compounds that modulate these pathways, while nanotechnology-enabled drug delivery systems (NDDSs) enhance precision and efficacy by targeting TAMs with minimal off-target effects. This review systematically examines the signaling networks between TAMs and LC cells, surveys cutting-edge TAM-reprogramming therapeutics, and evaluates nano-based strategies for combination therapy. Despite promising preclinical progress, we also address the challenges and future directions for translating TAM-targeted therapies into clinical practice. Liu et al.'s study demonstrated that SHP2 + TAMs serve as a theranostical target in nonsmall cell lung cancer (NSCLC). Through multiplex fluorescence analysis of 79 NSCLC specimens, we revealed that CD68 + SHP2 + TAMs are predominantly enriched in tumor regions (vs stroma) and correlate with poor overall survival (p < 0.05). Importantly, SHP2 expression was higher in M2-like (CD68 + CD206 + ) than M1-like (CD68 + CD86 + ) macrophages, with strong positive correlations between CD68 + SHP2 + and CD68 + CD206 + subsets across all TME compartments (p < 0.0001). These findings position SHP2 as a key regulator of M2-like TAM polarization and suggest that SHP2 inhibition could reprogram the immunosuppressive TME, offering a novel immunotherapeutic strategy for NSCLC. The spatial distribution patterns of SHP2 + TAM subpopulations provide critical insights for developing targeted therapies and predictive biomarkers.The occurrence and development of tumor plasticity is synergistically driven by the interaction between intrinsic regulation and the external microenvironment, in which the intrinsic regulatory network of tumor cells themselves plays a core leading role, and its importance is comparable to the interaction effect between the tumor microenvironment and immune cells. [5] Moreover, the key molecules in the regulatory network can govern the formation of malignant phenotypes and the establishment of environmental adaptability of tumor cells by regulating biological processes such as metabolism, epigenetics and cell cycle, and they also serve as core targets for the development of precision targeted therapy strategies. [6] Dysregulated lipid metabolism is a key hallmark of prostate adenocarcinoma progression. [7] Wang and Ying et al. study elucidates the critical role of stearoyl-CoA desaturase (SCD) in prostate adenocarcinoma (PRAD) progression through comprehensive multi-omics analyses. We identified elevated SCD expression in PRAD, associated with promoter hypermethylation and the L134V mutation, which correlated with increased tumor aggressiveness. Intriguingly, SCD levels showed positive associations with CD8+ T cell and macrophage infiltration, suggesting immunometabolic crosstalk in the tumor microenvironment. Single-cell RNA sequencing revealed cell-type specific SCD expression patterns, while functional enrichment analyses linked SCD to lipid/cholesterol biosynthesis and cell cycle pathways. Crucially, experimental validation demonstrated that SCD overexpression enhanced PRAD cell proliferation and invasion, while its knockdown exerted opposite effects. These findings position SCD as both a promising therapeutic target and prognostic biomarker in PRAD, particularly given the tumor's unique dependence on lipid metabolism. Tumor plasticity and immune microenvironment remodeling are the core drivers of gastric cancer malignant progression. Ye et al.'s study reveals the oncogenic role of AMBRA1 in driving stomach adenocarcinoma (STAD) progression through modulation of tumor plasticity and immune interactions. Comprehensive analyses demonstrated that elevated AMBRA1 expression correlates with poor patient survival and is associated with CD4+ T cell infiltration and cancerassociated fibroblast activity. Functional investigations showed that AMBRA1 depletion impairs STAD cell proliferation, migration, and invasion by inducing G1/S cell cycle arrest and promoting cellular senescence through H3K9me3-mediated epigenetic regulation. Notably, AMBRA1 inhibition enhanced chemosensitivity and significantly attenuated tumor growth in xenograft models. These findings position AMBRA1 as a promising therapeutic target, with dual mechanisms of action involving both tumor-intrinsic senescence induction and potential immune microenvironment modulation, offering new avenues for precision therapy in STAD. Dysregulated ribosome biogenesis and immune evasion are crucial mechanisms underlying the initiation and progression of B-cell malignancies. [8] Li and Meng et al. identified ribosomal protein L9 (RPL9) as a key oncogenic driver in B-cell acute lymphoblastic leukemia (B-ALL), operating through dual mechanisms. RPL9 is significantly overexpressed in B-ALL cells relative to normal B lymphocytes, and its knockdown (KD) inhibits proliferation, induces apoptosis in vitro, and prolongs survival in B-ALL xenografted NCG mice. Mechanistically, RPL9 KD disrupts ribosome biogenesis, triggers nucleolar stress, and activates the p53 pathway-an effect reversible by FTO overexpression, consistent with prior findings linking FTO-mediated m6A modification to RPL9 regulation. Notably, RPL9 depletion also enhances susceptibility to NK cell-mediated cytotoxicity by upregulating MICA/B, ligands for the NKG2D receptor. These findings establish RPL9 as a promising dual-function therapeutic target, offering a synergistic strategy that combines tumor suppression via p53 activation with immunotherapy enhancement through NK cell engagement.Childhood tumors, as malignant diseases that seriously threaten the life and health of adolescents, have long been limited by the predicaments of strong toxicity, high invasiveness and poor prognosis associated with traditional radiotherapy and chemotherapy, and the treatment response rate and quality of life of patients with high-risk cases still need to be urgently improved. [9,10] Neuroblastoma (NB), the most common pediatric extracranial solid tumor, remains challenging to treat, particularly in high-risk cases, with 5-year survival rates below 50% despite GD2-targeting immunotherapies. Characterized as immunologically "cold," NB tumors evade immune detection through impaired antigen presentation and immunosuppressive TMEs. The dysregulation of epigenetic mechanisms, such as DNA methylation, histone modifications, and chromatin remodeling, contributes to NB pathogenesis and justifies the pursuit of targeted therapies. Wang and Xu et al. reviewed the therapeutic potential of histone deacetylase inhibitors and DNA methyltransferase inhibitors, which offer advantages in development speed and cost-effectiveness. These agents may overcome the limitations of current immunotherapies and improve outcomes for high-risk NB patients. Retinoblastoma, the most common pediatric ocular malignancy, presents significant therapeutic challenges due to the severe complications-such as vision loss and systemic toxicity-associated with conventional treatments like chemotherapy, radiotherapy, and surgery. GD2-targeted immunotherapy offers a promising alternative by exploiting the tumor-specific expression of disialoganglioside GD2 while sparing normal tissues. Zhang et al. summarized recent advances in GD2-directed therapies, including: (1) Dinutuximab, an FDA-approved anti-GD2 monoclonal antibody initially developed for neuroblastoma and now under evaluation in retinoblastoma; (2) GD2-targeted CAR-T cell therapy; (3) GD2-based vaccines to stimulate adaptive immunity; and (4) nanoparticle delivery systems for enhanced targeting. These approaches demonstrate improved safety profiles and better quality-of-life outcomes compared to traditional modalities. However, challenges remain, particularly in achieving effective intraocular drug penetration, managing immune-related adverse events, and countering tumor immune evasion. This review critically assesses the current preclinical and clinical landscape of GD2 immunotherapy and proposes strategies-such as combination therapies and novel delivery systems-to overcome existing limitations.The individualized and precise regulation of immunotherapy is the key to improving diseases and their prognosis, and dynamic monitoring strategies during treatment are important supports for achieving this goal. The heterogeneity of B-cell regeneration kinetics poses challenges to treatment guidance. [11] Therefore, exploring the clinical application value of B-cell monitoring is of great practical significance. Dong and Yan et al. evaluated the clinical utility of B cell monitoring in 488 patients with autoimmune and transplant-related diseases undergoing rituximab (RTX) therapy from 2017 to 2024. While most patients exhibited B cell repopulation by 24 weeks post-treatment, a subset (6.8%) showed early repopulation within 4 weeks. Significant interpatient variability in B cell recovery kinetics was observed, underscoring the importance of regular B cell monitoring to guide individualized immunotherapy decisions, optimize treatment timing, and predict disease remission or recurrence. These findings support the implementation of standardized B cell surveillance protocols across diverse clinical indications.Epstein-Barr virus (EBV) infection is widespread and closely associated with a variety of malignant tumors and autoimmune diseases. Traditional EBV vaccine development is limited by bottlenecks such as insufficient antigen immunogenicity and poor targeting, while the combination of nanoparticle delivery systems and precise antigen epitope screening provides a new approach to break through this predicament. Li and Jiang et al.'s developed a novel nanoparticle-based vaccine targeting Epstein-Barr virus (EBV), addressing the urgent need for effective EBV prophylaxis. The vaccine features a glycan-free recombinant protein (L350), comprising five epitopes from the EBV gp350 glycoprotein's receptor-binding domain, validated for binding to host AKATA cells. L350 was displayed on self-assembling ferritin nanoparticles to enhance immunogenicity. In Balb/c mice, the L350-ferritin vaccine elicited strong antibody responses against both L350 and native gp350, and established durable antigen-specific B-cell memory. Importantly, vaccinated sera exhibited potent neutralizing activity, effectively inhibiting EBV-GFP infection in vitro. No histopathological abnormalities were observed, underscoring the vaccine's safety. These results position L350-ferritin as a promising EBV vaccine candidate, integrating rational epitope design with nanoparticle delivery to overcome prior development hurdles. The study provides both a specific prophylactic candidate and a versatile platform for future EBV vaccine development.This synthesis highlights how understanding immune cell plasticity in the TME informs the development of targeted therapies across diverse malignancies, while underscoring the need for continued investigation into combination approaches and treatment optimization strategies.

1,173 views

Emerging frontiers in epigenetic-targeted therapeutics for pediatric neuroblastoma
MINI REVIEW
25 July 2025
Emerging frontiers in epigenetic-targeted therapeutics for pediatric neuroblastoma
Xiaokang Wang, 3 more and Guiping Ma
Neuroblastoma (NB), the most prevalent extracranial solid malignancy in children, poses significant therapeutic challenges, particularly concerning high-risk subtypes characterized by an immunologically “cold” phenotype. These tumors evade immune surveillance through mechanisms such as impaired antigen presentation and immunosuppressive microenvironment formation. Despite the incorporation of immunotherapies (e.g., GD2 monoclonal antibodies) into international clinical guidelines, the 5-year survival rate of patients with NB persistently remains lower than 50%. Small-molecule targeted agents, distinguished by their low molecular weight and superior chemical stability, offer advantages over macromolecular antibody therapies by effectively penetrating cell membranes to engage intracellular targets. Epigenetic regulation, a DNA sequence-independent gene expression modulation system, plays a pivotal role in cell fate determination via dynamic DNA methylation, histone covalent modifications, chromatin spatial reorganization, and non-coding RNA-mediated pathways. Emerging evidence has highlighted a strong correlation between epigenetic dysregulation and NB progression, establishing a molecular rationale for novel therapeutic strategies. Current epigenetic research in NB primarily focuses on histone deacetylase inhibitors and DNA methyltransferase inhibitors. These drugs exhibit unique translational potential because of their accelerated development timelines and cost-effective production, significantly enhancing therapeutic accessibility. This review systematically examines the current landscape of epigenetic modulators in NB treatment and discusses their transformative potential in improving outcomes for high-risk patients with NB.

4,517 views

6 citations

ORIGINAL RESEARCH
27 March 2025
Ribosomal protein L9 is a potential therapeutic target for B-ALL through the activation of the p53 signaling pathway
Xinxin Li, 5 more and Dailing Si

2,923 views

5 citations

BackgroundEpstein–Barr virus (EBV) is a significant global public health concern because of its association with various malignancies and autoimmune diseases. Over 90% of the global population is chronically infected with EBV, impacting numerous cancer-related cases annually. However, none of the effective prophylactic vaccines against EBV is approved at present.MethodsIn this study, we developed a novel vaccine candidate based on epitope peptides from the receptor-binding domain of EBV-encoded gp350 glycoprotein to prevent EBV infection. These epitope peptides detected a binding capability with host cells were then fused by flexibility linkers and expressed in Escherichia coli to reduce the unnecessary glycan modifications to simulate their free-glycan status. The fused recombinant protein (L350) was displayed on the surface of ferritin-based nanoparticle. The immunogenicity of the L350–ferritin nanoparticle was evaluated in Balb/c mice, and the neutralizing titers of sera from immunized mice were detected by means of an infection blocking assay in an in vitro cell model.ResultsAll the five epitope peptides could bind to AKATA cells, and their fused recombinant protein (L350) was successfully presented on the surface of self-assembled ferritin nanoparticles. Sera from the L350–ferritin nanoparticle-immunized mice showed high titers of both L350 protein-specific and gp350D123 protein-specific antibodies, and sera from gp350D123 protein-immunized mice could also recognize L350 protein well. Most importantly, the L350–ferritin nanoparticle induced efficient neutralizing antibodies to block EBV-GFP infection in AKATA cells and also constructed a strong antigen-specific B-cell memory in immunized mice. Moreover, histopathological changes of main tissues from all vaccinated mice were not observed.ConclusionThese data indicate that the L350–ferritin nanoparticle vaccine candidate has considerable potential application in preventing EBV infection and provides a promising basis for developing prophylactic EBV vaccines.

5,698 views

16 citations

AMBRA1 drives gastric cancer progression through regulation of tumor plasticity
ORIGINAL RESEARCH
10 December 2024
AMBRA1 drives gastric cancer progression through regulation of tumor plasticity
Liuqi Ye, 7 more and Hai-Jing Zhong
BackgroundStomach adenocarcinoma (STAD) is an aggressive malignancy characterized by high tumor plasticity and heterogeneity. This study investigates the role of Autophagy and Beclin 1 Regulator 1 (AMBRA1) in regulating tumor plasticity in STAD progression.MethodsCombined with clinical data, the pan-cancer analysis of AMBRA1 was performed to analyze the role of AMBRA1 in STAD. Western blot, Flow Cytometry (FCM) assay, trans-well assay, wound healing assay, MTT, Reactive Oxygen Species (ROS) assay, Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) and staining were performed to study the effects of AMBRA1 in AGS human gastric cancer cells. An AGS gastric cancer xenograft model was constructed to further verify the role of AMBRA1 in the development of STAD.ResultsAMBRA1 overexpression correlated with poor overall survival in STAD and was positively associated with T cell CD4+ infiltration. High AMBRA1 expression also indicated worse prognosis in patients with high cancer-associated fibroblast infiltration. AMBRA1 depletion suppressed STAD cell proliferation, migration, and invasion in vitro. Mechanistically, AMBRA1 knockdown induced G1/S cell cycle arrest and triggered cellular senescence through epigenetic alterations, including changes in H3K9me3 levels. AMBRA1 inhibition also sensitized STAD cells to chemotherapeutic agents. In vivo studies confirmed the tumor-suppressive effects of AMBRA1 loss, resulting in reduced tumor growth and increased cellular senescence.ConclusionsOur findings uncover an oncogenic role for AMBRA1 in STAD. Targeting AMBRA1 may induce tumor cell senescence, apoptosis, and potentiate anti-tumor immunity, providing a rationale for developing AMBRA1-targeted precision therapies to improve clinical outcomes in STAD patients.

4,632 views

8 citations

ORIGINAL RESEARCH
25 November 2024
The monitoring of B lymphocytes in non-lymphoma patients following rituximab treatment
Linjie Dong, 8 more and Yangjuan Bai

4,202 views

5 citations

Prospects of anti-GD2 immunotherapy for retinoblastoma
REVIEW
15 November 2024
Prospects of anti-GD2 immunotherapy for retinoblastoma
Xinlong Zhang, 5 more and Jingjing Li

6,706 views

13 citations

SMAD4 enhances the cytotoxic efficacy of human NK cells against colorectal cancer cells via the m6A reader YTHDF2
ORIGINAL RESEARCH
7 October 2024
SMAD4 enhances the cytotoxic efficacy of human NK cells against colorectal cancer cells via the m6A reader YTHDF2
Xinxin Li, 2 more and Siyong Huang
Colorectal cancer (CRC) ranks as the third most prevalent malignant neoplasm in terms of both morbidity and mortality. Within the tumor microenvironment (TME) of CRC, the diminished presence and diminished cytotoxic function of natural killer (NK) cells serve as primary factors driving the advancement of CRC; however, the precise regulatory mechanisms governing this phenomenon remain incompletely understood.Consequently, the identification of novel, potential anti-CRC targets associated with NK cells emerges as a pressing and paramount concern warranting immediate attention.We examined the regulatory mechanism of SMAD4-mediated NK cell cytotoxicity on CRC by utilizing samples from CRC patients, mouse models of CRC, and various experimental techniques. Our findings revealed that the expression of SMAD4 is decreased in NK cells within the TME of human CRC. Furthermore, we observed that enforced upregulation of SMAD4 resulted in enhanced cytotoxicity of NK cells towards CRC cells. Furthermore, our research has revealed that YTHDF2 functions as a downstream effector of SMAD4, playing a crucial role in the control of transcription and translation of m 6 A-modified RNA. Moreover, our investigation demonstrated that increased expression of SMAD4 promoted the activated receptor NKG2D by elevating levels of YTHDF2. Ultimately, the SMAD4-YTHDF2 regulatory axis-significantly enhanced the cytotoxicity of NK cells against human CRC cells. Our study unveils a novel mechanism through which SMAD4 modulates the cytotoxicity of NK cells towards CRC cells, suggesting that SMAD4 may hold promise as a potential therapeutic target for NK cell therapy in CRC.

3,670 views

9 citations

Natural killer cells: a future star for immunotherapy of head and neck squamous cell carcinoma
REVIEW
21 August 2024
Natural killer cells: a future star for immunotherapy of head and neck squamous cell carcinoma
Shuyan Dong, 8 more and Hongjiang He
The interplay between immune components and the epithelium plays a crucial role in the development and progression of head and neck squamous cell carcinoma (HNSCC). Natural killer (NK) cells, one of the main tumor-killing immune cell populations, have received increasing attention in HNSCC immunotherapy. In this review, we explore the mechanism underlying the interplay between NK cells and HNSCC. A series of immune evasion strategies utilized by cancer cells restrict HNSCC infiltration of NK cells. Overcoming these limitations can fully exploit the antineoplastic potential of NK cells. We also investigated the tumor-killing efficacy of NK cellbased immunotherapies, immunotherapeutic strategies, and new results from clinical trials. Notably, cetuximab, the most essential component of NK cell-based immunotherapy, inhibits the epidermal growth factor receptor (EGFR) signaling pathway and activates the immune system in conjunction with NK cells, inducing innate effector functions and improving patient prognosis. In addition, we compiled information on other areas for the improvement of patient prognosis using anti-EGFR receptor-based monoclonal antibody drugs and the underlying mechanisms and prognoses of new immunotherapeutic strategies for the treatment of HNSCC.

5,201 views

10 citations

ORIGINAL RESEARCH
16 September 2024
Comprehensive analysis of stearoyl-coenzyme A desaturase in prostate adenocarcinoma: insights into gene expression, immune microenvironment and tumor progression
Jie Wang, 7 more and Yun-Jun Ge

3,975 views

4 citations

Background: Tumor-associated macrophages (TAMs) constitute a plastic and heterogeneous cell population of the tumor microenvironment (TME) that can regulate tumor proliferation and support resistance to therapy, constituting promising targets for the development of novel anticancer agents. Our previous results suggest that SHP2 plays a crucial role in reprogramming the phenotype of TAMs. Thus, we hypothesized that SHP2+ TAM may predict the treatment efficacy of non-small cell lung cancer NSCLC patients as a biomarker. Methods: We analyzed cancer tissue samples from 79 NSCLC patients using multiplex fluorescence (mIF) staining to visualize various SHP-2+ TAM subpopulations (CD68+SHP2+, CD68+CD86+, CD68+206+, CD68+ CD86+SHP2+, CD68+ CD206+SHP2+) and T cells (CD8+ Granzyme B +) of immune cells. The immune cells proportions were quantified in the tumor regions (Tumor) and stromal regions (Stroma), as well as in the overall tumor microenvironment (Tumor and Stroma, TME). The analysis endpoint was overall survival (OS), correlating them with levels of cell infiltration or effective density. Cox regression was used to evaluate the associations between immune cell subsets infiltration and OS. Correlations between different immune cell subsets were examined by Spearman’s tests. Results: In NSCLC, the distribution of different macrophage subsets within the TME, tumor regions, and stroma regions exhibited inconsistency. The proportions of CD68+ SHP2+ TAMs (P < 0.05) were higher in tumor than in stroma. And the high infiltration of CD68+SHP2+ TAMs in tumor areas correlated with poor OS (P < 0.05). We found that the expression level of SHP2 was higher in M2-like macrophages than in M1-like macrophages. The CD68+SHP2+ subset proportion was positively correlated with the CD68+CD206+ subset within TME (P < 0.0001), tumor (P < 0.0001) and stroma (P < 0.0001). Conclusions: The high infiltration of CD68+SHP2+ TAMs predict poor OS in NSCLC. Targeting SHP2 is a potentially effective strategy to inhibit M2-phenotype polarization. And it provides a new thought for SHP2 targeted cancer immunotherapy.

5,161 views

12 citations